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Abstract 
In recent years, drug abuse has posed a great threat to public health. Among abused 
drugs, prescription opioids have caused a significant problem. Oxycodone is a 
pervasive semi-synthetic prescription opioid, indicated for treatment of moderate to 
severe pain. Marked as a Schedule II controlled substance, it possesses a high 
potential for abuse. Along with Hydrocodone and Methadone, Oxycodone has become 
one of the three most commonly overdose-involved prescription opioids. Previous 
studies indicate that the combination of oxycodone and benzodiazepines can render 
higher overdose liability and stronger effects. Other researchers have examined their 
pharmacological interactions by experiments and explained this problem’s severity 
from statistical angle. As both drugs undergo phase I metabolism through CYP 3A4 
enzyme, we believe that their concurrent use produces drug-drug interactions (DDIs), 
leading to increased plasma concentration and prolonged CNS effects. The goal of my 
research is to quantitatively simulate the concentration-time profiles of oxycodone 
co-administered with diazepam (a type of benzodiazepines). First, we performed 
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statistical analysis of 40,996 records in FDA Adverse Event Reporting System 
(FAERS) for oxycodone. The result shows that most death outcomes involve 
concomitant use of oxycodone with other drugs, and that about half of these 
co-administrations include benzodiazepines, which manifests the significance of this 
problem. Based on the pharmacokinetic data of oxycodone administered in different 
doses, we built a one-compartment model with first-order dosing and linear 
elimination. Using the model, we obtained the parameters of single oxycodone 
pharmacokinetic simulations. With the foundation of the model and parameters, we 
simulated the oxycodone concentration-time profile in the case of concomitant use 
with diazepam and drew the conclusion. While co-administered with Diazepam, the 
metabolism of Oxycodone is delayed and renders more threatening overdose 
symptoms. By conducting the quantitative simulations on pharmacokinetic profiles of 
oxycodone and its high-risk DDIs, we explored the potential threshold of this 
overdose and provided rational drug use instructions.  
 
Key words: Drug Abuse; Co-administration; Oxycodone; Diazepam; ODE Model; 
Compartment models; Quantitative Simulation 
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1.0 INTRODUCTION 
1.1 DRUG ABUSE 
Drug abuse has posed serious issues to public health. Drugs with abuse liability can 
be grouped as stimulants, analgesics & narcotics, hypnotics as well as antidepressants, 
nicotine and alcohol [1]. In this section, we would like to focus on the abuse study of 
prescription opioid, a class of analgesics & narcotics. Over the past 15 years, the use 
of opioid pain killers in the United States has soared [2]. In 2012, epidemiologic data 
indicate that 12.5 million Americans reported the abuse of prescription opioids [3]. 
During 2014, 28647 drug overdose deaths involve opioids [4]. The majority of 
overdose deaths are caused by concomitant use of multiple prescribed or illicit 
substances, with the most common factor, benzodiazepines. Previous data have 
supported this fact. In 2008, 62% of the emergency department visits for narcotic 
analgesics involved multiple drugs and among them, including alcohol, 26% involved 
benzodiazepines use [5]. Benzodiazepines are also pervasively abused drugs. In 2011, 
426000 emergency department visits in the US involves nonmedical use of 
benzodiazepines [6]. 
People have come up with several ways to solve the drug abuse issues, like policy 
alteration, physician training, patient education and monitoring programs. However, 
none of these solutions seems effective. Numerous of problems appear in the process. 
The treatment of prescription opioid addiction has long been neglected. Neither 
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pharmacotherapy nor behavioral treatment presents sufficient efficacy. The 
prescription drug monitoring programs are hard to conduct as the difficulty to find the 
data [7].What makes the problem more complex is the use of prescription opioids all 
depends on the patients themselves. In the view of experts, the recovery is likely best 
achieved through a combination of pharmacotherapy and counselling [8].  
Given the dilemma of drug abuse investigation, my research project proposes to 
conduct the quantitative simulation of a prescription opioid, oxycodone and its 
co-administration with a benzodiazepine, diazepam. By exploring the potential 
threshold of overdose, we hope to better assess the risk of toxicity, provide the 
rational drug use instructions and help the decision making.  
 
1.2 OXYCODONE 
 
 
Figure1. Chemical structure of Oxycodone  
 
Oxycodone, (14-hydroxy-7, 8-dihydrocodeinone, C18H21NO4) [9], is a semi-synthetic 
opioid [10] and pervasive narcotic analgesic, indicated for the treatment of moderate 
to severe pain. Oxycodone can be administered orally, rectally, intraspinally and 
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parentally [11]. In my research, I choose the controlled-release oral formulation of 
oxycodone to study. This kind of oxycodone is sold under the brand name OxyContin. 
The oral bioavailability is about 60%-87% [10]. As a controlled-release drug, 
OxyContin has a two-phase release-absorption process, with two half-lives, 0.6h and 
7h and its plasma half-life is between 3-5 h [10].The dosage forms include 10, 15, 20, 
30, 40, 60,80 mg film-coated tablets while the dosing regimen varies individually. 
 
                  (a)                                       (b) 
 
Figure 2. Crystal structure of active mu-opioid receptor bound to agonist BU72 (PDB ID: 5C1M)       
(a) Membrane view  (b) Extracellular view 
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Figure 3. Oxycodone mechanism of action 
 
Oxycodone achieves its pharmacological effect through binding to opioid receptors 
located in central, peripheral and autonomous nervous systems. Opioid receptors are 
seven-transmembrane G-protein-coupled receptors (GPCR). By coupling to 
G-proteins, these receptors trigger a cascade of intracellular activities. The Gα subunit 
interacts with potassium channel, Kir3, rendering cellular hyperpolarization and tonic 
neural activity inhibition [12]. Besides this, opioid receptors cause Ca2+ influx 
reduction and adenylate cyclase inhibition. Finally, these activities inhibit spinal cord 
pain transduction and reach the analgesic effect. 
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Oxycodone is marked as a Schedule II controlled substance which means it has a high 
potential for abuse. There are specific terms in OxyContin label about drug overdose 
which is primarily manifested by respiratory depression. The occupancy of opioid 
receptors renders reduced ventilator frequency and pattern. Such activity profoundly 
depresses the HVR (hypoxic ventilator response) and HCVR (hypercapnic ventilator 
response). Previous investigations on rats show that pre-Bötzinger complex and 
retro-trapezoid and parafacial respiratory group (RTN/pFRG) play a vital role in 
respiratory depression. The pre-Bötzinger complex and the RTN/pFRG are small 
areas in the brainstem that can generate respiratory rhythm [13]. The pre-Bötzinger 
complex is active during expiration and the pre-Bötzinger complex is active during 
inspiration. However, the pre-Bötzinger complex can be inhibited by opioids while 
the pre-Bötzinger complex is not affected. As a result, this different sensitivity to 
opioids leads to an irregular respiratory rhythm. Although this theory hasn’t been 
verified in humans, it provides a possible explanation for opioid-induced respiratory 
depression.  
 
1.3 DIAZEPAM 
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Figure 4. Chemical structure of Diazepam 
 
Diazepam(DZP),7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-on
e [14], C16H13CLN2O) , a type of benzodiazepines, was launched to the market in 
1963 [15]. With the brand name, Valium, it is indicated for anxiety disorders, epilepsy, 
muscle spasms, and alcohol withdrawal. The bioavailability ranges from 93 to 100% 
orally [16] which is relatively high. When delivered orally, diazepam will reach the 
peak plasma level (Cmax) pretty soon, just 30-60 min after administration [16]. 
However, as the diazepam metabolites are active, the half-life can be as long as 24 to 
48 h [17]. The initial dosage regimen for adults is between 2 to 10 mg orally, 2-4times 
daily.  
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Figure 5. GABA receptors [18] 
 
 
Figure 6. Diazepam mechanism of action 
 
 
In terms of its high lipophilicity [19] and protein binding rate, diazepam has a rapid 
onset [20] and can easily cross the blood-brain barrier which means it possesses 
central nervous system (CNS) effect. Diazepam can be regarded as a positive 
allosteric modulator of GABAA receptors [21]. This receptor is a ligand-gated 
chloride-selective ion channel, composed of 5 glycoprotein subunits, 2α, 2 β and 1γ 
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subunit [22] . By binding to a site far from GABA binding site, diazepam causes the 
conformational change and activates GABAA receptors. This gives rise to increased 
chloride conductance as well as the frequency of channel openings [23]. As GABA is 
the most common neurotransmitter in CNS and has an inhibitory nature, such activity 
significantly reduces the excitability of neurons [22]. 
 
The typical side effects of diazepam are manifested by psychomotor retardation, 
memory impairment, paradoxical disinhibition, depression and emotional blunting 
[24]. Diazepam is marked as schedule IV controlled substance [25]which means it 
also possesses abuse potential. Under the FDA instructions, diazepam should be used 
very cautiously in patients with drug abuse history. There is potential drug-drug 
interactions (DDIs) existing. The overdose symptoms of benzodiazepines are CNS 
depression, ranging from drowsiness to coma. 
 
1.4 CO-ADMINISTRATION MECHANISM 
Both Oxycodone and diazepam are mainly metabolized in the liver. After oral 
administration, oxycodone undergoes phase I metabolism via CYP3A4 and CYP2D6. 
Generally, 45% of oxycodone is N-demethylated to Noroxycodone by CYP3A4 and 
another 11% is O-demethylated to Oxymorphone through CYP2D6 [26]. The main 
metabolite Noroxycodone is relatively inactive while Oxymorphone is active [27]. In 
this way, it can be seen that the parent drug produces pharmacological effects. The 
metabolic pathway is shown as follows.  
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Figure 7. Oxycodone metabolic pathway[28] 
 
The metabolism of diazepam is mediated in the liver through cytochrome P450 
(CYP450) enzymes, mostly CYP3A4 and CYP2C19 [29]. Diazepam is metabolized to 
nordiazepam via N-demethylation and temazepam by C3 hydroxylation [30]. Both 
nordazepam and temazepam will be metabolized to oxazepam [31]. The three main 
diazepam metabolites nordiazepam, temazepam and oxazepam are all active and have 
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been marketed as drugs [16]. This fact explains why diazepam has a long half-life and 
consistent efficacy. The metabolic pathway of diazepam is as follows. 
 
 
Figure 8. Diazepam metabolic pathway [18] 
 
From the two metabolic pathway figures, we can see that both oxycodone and 
diazepam are metabolized by CYP3A4 enzyme. According to the data from 
SuperCYP, diazepam can be considered as substrate and inhibitor of CYP3A4. It is 
already known that both inhibitors and substrates of a particular CYP isozyme 
decrease the metabolism of substrates of that enzyme. As mentioned, oxycodone has 
neural inhibitory function as well as diazepam triggers inhibitory-natured 
neurotransmitter GABA. We propose that there is potential drug-drug interactions 
(DDIs) between these two drugs. This DDI can lead to higher plasma concentration 
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and prolonged CNS effects. The combination produces additive or synergistic effect, 
increasing the risk of acute harms such as overdose [32]. 
 
  
 
 
Figure 9. Drug-drug interaction on SuperCYP 
S: Substrate, Inh: Inhibitor 
 
             
1.5 CO-ADMINISTRATION CONTEXT 
Certain medications, for example, analgesics, antidepressants and anxiolytics, have 
been identified as significant risk factors in adverse drug events [33]. The top 10 
drugs involved in drug overdose deaths in the United States from 2010 to 2014 belong 
to 3 drug classes: opioids, benzodiazepines and stimulants [34]. Recent studies have 
reported a rise in oxycodone abuse and the majority of deaths attributable to 
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oxycodone are cases of combined drug toxicity. Oxycodone, as a commonly-used 
narcotic analgesic, ranks within top 3 throughout the years [34]. In the meantime, 
diazepam, a member of benzodiazepine family, has been listed in this rank for five 
years [34]. Previous researches have reported a the majority of deaths attributable to 
oxycodone are cases of combined drug toxicity [35]. Among all these combination 
cases, benzodiazepines are the most pervasive co-toxicants [35]. 
There are plenty of studies showing these two drugs have been used together for 
medical or non-medical purposes. It is widely believed that co-prescription of opioid 
with other medications may assist in the management of chronic pain [36]. For 
instance, sometimes Oxycodone and Diazepam are used concurrently in chronic 
nonmalignant pain (CNMP) patients on long-term opioid treatment related to anxiety 
or sleep disorders [37].  However, if people take prescription opioids and 
benzodiazepines concurrently at supratherapeutic doses in recreational settings, or 
take the drugs in a manner not prescribed by the physician, the degree of adverse 
effects, especially respiratory depression, can render serious medical consequences 
[38]. Such evidence emphasizes the need of better patient education, close patient 
monitor and thorough benefit-risk assessment when prescribing these drugs in 
combination [33]. 
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2.0 METHODS 
2.1 SOFTWARE 
The aim of our research is to quantitatively describe the concentration-time profile of 
oxycodone and its co-administration with diazepam which is related to the emerging 
science, pharmacometrics. It is designed to conduct quantitative analysis of 
pharmacokinetic and pharmacodynamic data [39]. In this section, I want to introduce 
a few softwares usually applied to pharmacometrics study, for example, NONMEM, 
Matlab, R, SIMCYP Simulator, Monolix, Simulx, PFIM, PopED, win(open)BUGS 
[40]. 
NONMEM, which was introduced in 1982, is the acronym of NON-linear Mixed 
Effects Modeling [41].  Just as the name implies, NONMEM has been significantly 
applicable to population PK/PD studies. This software considers the nonlinear 
regression models which are capable of estimating population PK/PD parameters [42]. 
The latest version of NONMEM is 7.3.0 with Monte Carlo expectation-maximization 
and Markov Chain Monte Carlo Bayesian methods added in 2013. 
R is a programming language and software environment for statistical computation 
and graphics [43]. It contains linear and nonlinear modeling, statistical tests, 
time-series analysis, clustering, classification and so on. An R package called RxODE 
to solve ordinary differential equations (ODEs) and perform simulations in 
pharmacometric models [44]. The latest R 3.3.3 will be released on March 6, 2017.  
SIMCYP is a platform and database for bottom-up mechanistic modeling and 
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absorption, distribution, metabolism and excretion (ADME) simulation [45]. It takes 
into account the factors like experimental data, dosage forms, drug properties and 
population variances. SIMCYP is capable of handling enormous physiologically 
based pharmacokinetic and pharmacodynamic (PBPK/PD) models. In recent years, 
this software has evolved from a simple DDI tool to a sophisticated and 
comprehensive model based drug development (MBDD) platform that covers the 
whole drug development process [46]. Now it’s been developed to version 16. 
Matlab, abbreviation of matrix laboratory, is a multi-paradigm numerical computing 
environment. I will focus on the introduction of SimBiology, the Matlab package I 
utilized in my research. According to the SimBiology tutorial, it is a versatile tool to 
model, simulate and analyze dynamic systems, especially focusing on PK/PD and 
system biology studies. The operation procedure of SimBiology is as add data—add 
model—add task. In this way, first users add experimental or any sort of data, then 
build the model. These models can be imported from the built-in PK libraries or 
created individually. It’s also feasible to integrate the inset PK models with 
customized system biology models. In the model session, we can set various 
parameters. The last step will be “Add task” where a number of commands can help 
users implement analysis. For instance, the ‘Fit data’ option can be applied to 
population pharmacokinetics. Generally, the simulation is based on ODEs. However, 
if none of the commands can meet the researchers’ needs, then they can use ‘create 
custom analysis’ to generate their own codes. A great many pharmaceutical researches 
can be achieved by SimBiology, such as population pharmacokinetic modeling in 
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using nonlinear mixed-effects methods, using system pharmacology modeling 
approaches to guide preclinical animal studies and integrating PK/PD and mechanistic 
modeling. The upgrade of SimBiology is together with Matlab which is R2016b 
version now. 
 
 
   
 
 
Figure 10. Interface of SimBiology 
 
2.2 COMPARTMENT MODELS 
2.2.1 One-compartment model 
Compartment model is a robust tool for PK study. The simplest form is the one 
compartment model. This model assumes the whole body is a single system called 
central compartment. 
16 
 
 
 Figure 11. Diagram of one compartment model 
The compartment is characterized by distribution volume Vd. As we choose the oral 
administration, the input depends on dose and absorption rate Ka while the output is 
described by elimination rate Ke. In most cases, we consider Ka, Ke as first order 
terms which means the relationship between ln(concentration) and time is linear.  
 
Figure 12. ln(c) versus time profile (first order) 
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Basic solution for concentration-time profile is: 
𝑑𝐶
𝑑𝑡
= −𝑘𝐶𝑛 
C is the concentration, n is the order number, and k represents the constant. 
First order means n=1, 
𝑑𝐶
𝑑𝑡
= −𝑘𝐶.  
While taking absorption rate into account, 
𝑑𝐶
𝑑𝑡
= 𝐾𝑎𝐷 − 𝐾𝑒𝐶 
The general denotation of initial concentration value C0. [47]  
𝐶0 =
𝐷
𝑉𝑑
 
D is the dose, Vd is the volume of distribution. 
However, for oral dose, C0 cannot be directly used as the simple form. Thus, we use 
the Cmax to replace C0. [48] 
𝐶𝑚𝑎𝑥 =
𝑓𝐷
𝑉𝑑𝑒
 
Cmax is the maximum concentration the drug can reach in a certain compartment 
(usually in plasma), F is the bioavailability, e is the base of natural logarithms. 
The solution of the ubiquitous function: [49] 
 
C =
𝑓𝐷
𝑉𝑑
𝐾𝑎
𝐾𝑎 − 𝐾𝑒
[exp(−𝐾𝑒𝑡) − exp(−𝐾𝑎𝑡)] 
 
2.2.2 Two-compartment model 
In this case, the body is taken as two compartments, central and peripheral. Central 
compartment is the site where the drug well distributes. Correspondingly, the 
18 
 
peripheral compartment only has limited number of drug molecules existing.  
 
Figure 13. Diagram of two-compartment model 
V1 is the distribution volume of central compartment, V2 is the distribution volume of 
peripheral compartment, K12 is the distribution rate, K21 is the redistribution rate. 
We still adopt first-order elimination. 
𝑑𝐶
𝑑𝑡
= −𝑘𝐶 
The general solution for two-compartment model concentration (i.v.). [50] 
C = A𝑒−𝛼𝑡 + 𝐵𝑒−𝛽𝑡 
The general solution for oral administration. [51] 
C = A′𝑒−𝛼𝑡 + 𝐵′𝑒−𝛽𝑡 + 𝐶𝑒−𝑘𝑎𝑡 
The solution of the ubiquitous function: [52] 
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C = 𝐾𝑎𝐶0[
(𝐾21 − 𝛼)
(𝐾𝑎 − 𝛼)(𝛽 − 𝛼)
𝑒−𝛼𝑡 +
(𝐾21 − 𝛽)
(𝐾𝑎 − 𝛽)(𝛼 − 𝛽)
𝑒−𝛽𝑡
+
(𝐾21 − 𝐾𝑎)
(𝛼 − 𝐾𝑎)(𝛽 − 𝐾𝑎)
𝑒−𝛼𝑡] 
 
Here C0 is the absorbed concentration. Therefore, the solution should be transformed 
to: 𝐶0 =
𝑓𝐷
𝑉1
 
α,β term can be obtained through equations below: [53] 
b = 𝐾12 + 𝐾21 + 𝐾𝑒 
 
α =
𝑏 + √𝑏2 − 4𝐾21𝐾𝑒
2
 
 
β =
𝑏 − √𝑏2 − 4𝐾21𝐾𝑒
2
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Figure 14. ln(concentration) versus time profile of two-compartment model 
In the plot of concentration-time profile, the figure can be divided to 2 linear parts, 
distribution and elimination phase, with the slope of -α and -β respectively. 
Besides one-compartment and two-compartment models, we can use any number of 
compartments to study pharmacokinetic problems. Generally speaking, the more 
compartments, the more accurately the question will be identified. However, restricted 
by time, labor, financial cost, researchers are not able to adopt models with enormous 
compartments. Also, there is no golden standard to instruct the model usage. People 
should choose the model according to their own conditions. 
 
2.3 Kinetic Models & Drug-Drug Interaction 
2.3.1 Metabolite formation kinetics 
As this is an enzyme involved reaction, we adopted Michaelis-Menten Kinetics [54]: 
 
v =
𝑉𝑚𝑎𝑥×𝑆
𝐾𝑚 + 𝑆
 
 
v represents the metabolite formation of velocity, Km the Michaelis-Menten constant 
of the substrate, Vmax the maximum formation velocity for the enzyme, and S the 
substrate concentration [55]. 
To apply the Michaelis-Menten Kinetics, we need to introduce the new formula to 
demonstrate this equation. As mentioned in Chapter 1.3, diazepam can be regarded as 
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the substrate and inhibitor of CYP3A4 which means this is an inhibition model. There 
are three typical types, competitive, noncompetitive and uncompetitive inhibition.  
In competitive inhibition, the inhibitor competes with the substrate at the enzyme’s 
same active site.  
E + S ↔ ES → E + P 
E + I ↔ EI 
 
E is the enzyme, S is the substrate, ES is the substrate-enzyme complex, P is the 
product, I is the inhibitor, EI is the enzyme-inhibitor complex [56]. 
The Km of competitive inhibition could be illustrated as: 
 
𝐾𝑚(𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛) = 𝐾𝑚×(1 +
𝐼
𝐾𝑖
) 
 
v =
𝑉𝑚𝑎𝑥×𝑆
𝐾𝑚 (1 +
𝐼
𝐾𝑖
) + S
 
 
Ki is the dissociation constant of the inhibition-enzyme complex. 
As the inhibitor only reacts with the enzyme, more substrate needs more inhibitor. 
As to noncompetitive inhibition, in addition to binding with the substrate itself, the 
inhibitor also binds to the enzyme-substrate complex. The binding usually happens at 
a site remote from active site. 
E + S ↔ ES → E + P 
E + I ↔ EI 
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EI + S ↔ EIS 
ES + I ↔ EIS 
 
𝑉max (𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛) =
𝑉𝑚𝑎𝑥
(1 +
𝐼
𝐾𝑖
)
 
 
v =
𝑉𝑚𝑎𝑥×𝑆
(1 +
𝐼
𝐾𝑖
)
𝐾𝑚 + 𝑆
 
 
Noncompetitive inhibitor is not affected by the concentration of substrate. It exerts 
inhibition mainly through reducing the binding affinity of substrate or enzyme. 
About uncompetitive model, instead of the substrate, the inhibitor only binds to the 
substrate-enzyme complex. 
E + S ↔ ES → E + P 
ES + I ↔ EIS 
𝐾𝑚(𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛) = 𝐾𝑚×(1 +
𝐼
𝐾𝑖
) 
𝑉max (𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛) =
𝑉𝑚𝑎𝑥
(1 +
𝐼
𝐾𝑖
)
 
v =
𝑉𝑚𝑎𝑥×𝑆
(1 +
𝐼
𝐾𝑖
)
𝐾𝑚(1 +
𝐼
𝐾𝑖
) + 𝑆
 
 
To inhibit such reaction, we need higher concentration of substrates and enzymes.  
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In terms of the limited number of binding sites on CYP 3A4 and the same kind of 
chemical reaction these two drugs conduct (N-methylation), we speculate that this is a 
competitive inhibition. Oxycodone and Diazepam bind to the same CYP3A4 active 
site. 
 
2.3.2 Two identical site competition model 
Because Oxycodone and Diazepam both undergo phase I metabolism through 
CYP3A4 and N-demethylated to Noroxycodone and nordiazepam, respectively, we 
consider them as a two-site model with competition [57]. The scheme of this model is 
shown as below. 
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Figure 15. Scheme of two site competition model for oxycodone and diazepam 
E: CYP3A4 enzyme, S: oxycodone, A: diazepam, P1: diazepam metabolite, P2: 
oxycodone metabolite, Ks: oxycodone binding affinity, Ka: diazepam binding affinity, 
Kps: catalytic rate of oxycodone, Kpa: catalytic rate of diazepam, α: the factor how 
diazepam affects oxycodone binding, β: the factor how oxycodone affects diazepam 
binding, γ: the factor how the complex SEA affects diazepam reaction, δ: the factor 
how the complex SEA affects oxycodone reaction. If α, β, γ, δ >1, the rate is increased, 
α, β, γ, δ <1, the rate is decreased. 
Hill equation: 
𝑣
𝑉𝑚𝑎𝑥
=
𝑆𝑛𝐻
𝑆0.5
𝑛𝐻 + 𝑆𝑛𝐻
 
 
S0.5 is the substrate concentration when v =
𝑉𝑚𝑎𝑥
2
, nH is the Hill coefficient [58]. The 
Hill equation was introduced by A.V. Hill [59]. The equation is derived from a 
binding reaction scheme [60]. It is a very useful tool for ligand concentration 
estimation and determining the degree of cooperativity of the ligands binding to the 
enzyme [60].  
To put the equation into this kinetic model, we change the form of Hill equation to: 
 
𝑣
𝑉𝑚𝑎𝑥
=
𝑆
𝐾𝑠
+
𝑆2
𝛼𝐾𝑆
2 +
𝛾 ∙ 𝛿 ∙ 𝑆 ∙ 𝐴
𝛼 ∙ 𝛽 ∙ 𝐾𝑆 ∙ 𝐾𝑎
1 +
2𝑆
𝐾𝑆
+
𝑆2
𝛼𝐾𝑠2
+
2𝑆𝐴
𝛼𝛽𝐾𝑆𝐾𝑎
+
2𝐴
𝐾𝑎
+
𝐴2
𝛽𝐾𝑎2
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2.3.3 Drug-drug interaction 
To measure the degree of inhibition, we use the formula: 
 
R =
𝑣(+𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟)
𝑣(−𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟)
=
1
1 +
𝐼
𝐾𝑖
 
 
v(+inhibitor) is the metabolic rate with inhibition while v(-inhibitor) is without 
inhibition. 
First, we need to determine the hepatic clearance CLh. Three models can be used to 
quantify the CLh. 
Well-stirred model [61]:  
 
𝐶𝐿ℎ =
𝑄ℎ ∙ 𝑓𝑢 ∙ 𝐶𝐿𝑖𝑛𝑡
𝑄ℎ + 𝑓𝑢 ∙ 𝐶𝐿𝑖𝑛𝑡
 
 
Parallel tube model [61]: 
 
𝐶𝐿ℎ = 𝑄ℎ[1 − exp (−
𝑓𝑢 ∙ 𝐶𝐿𝑖𝑛𝑡
𝑄ℎ
)] 
Dispersion model[61]: 
 
𝐶𝐿ℎ = 𝑄ℎ[1 −
4𝑎
(1 + 𝑎)2 exp [
(𝑎 − 1)
2𝐷𝑛 ] −
(1 − 𝑎)2 exp [−
(𝑎 + 1)
2𝐷𝑛 ]
] 
 
a = √1 + 4𝑅𝑛𝐷𝑛 
 
Rn =
𝑓𝑢 ∙ 𝐶𝐿𝑖𝑛𝑡
𝑄ℎ
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CLint is the intrinsic clearance, Qh is the hepatic drug flow, fu is the blood unbound 
fraction, Dn is the axial dispersion number, Rn is the efficiency number [62]. 
fℎ =
𝐶𝐿ℎ
𝐶𝐿ℎ + 𝐶𝐿𝑟
 
 
𝑓𝑚 =
𝐶𝐿𝑖𝑛𝑡,1
𝐶𝐿𝑖𝑛𝑡,1 + 𝐶𝐿𝑖𝑛𝑡,2
 
 
fh is the fraction of hepatic clearance in total clearance, CLr is the renal clearance, fm 
is the fraction of the metabolic process subject to inhibition in CLh, CLint,1 and CLint,2 
are the intrinsic clearance for the metabolic pathway inhibited and not inhibited. 
For orally administered drugs, the degree of inhibition can be expressed as: 
 
R =
𝐴𝑈𝐶𝑝𝑜(+𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟)
𝐴𝑈𝐶𝑝𝑜(−𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟)
 
=
1
𝑓ℎ∙
𝐶𝐿ℎ
′
𝐶𝐿ℎ
+ 1 − 𝑓ℎ
∙
𝐹ℎ
′
𝐹ℎ
 
 
Fh is the hepatic availability. 
In this way, we’ll be able to predict the change of the AUC value. 
To figure out the differential equations, we need the stoichiometric matrix [63]. 
The general form of the matrix is as follows. 
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Primary means primary compound, secondary means secondary compound. Type A, B, 
C are metabolic pools. A: biochemical element conservation. B: conservation of 
exchanged biochemical moiety.  C: cofactor conservation. [64] 
 
 
Figure 16. Reaction map of the Oxycodone and Diazepam enzymatic reactions 
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Figure 17. Compound map of the Oxycodone and Diazepam enzymatic reactions 
Oxycodone: O, Diazepam: D, CYP3A4: E, Oxycodone met: OM, Diazepam met: 
DM. 
 
There are several ways to describe generalized reaction rate [65]. 
Linear approximation:  
r = 𝑟0 + 𝑘(𝑒 − 𝑒0) + ∑ 𝑘𝑖(𝑐𝑖 − 𝑐0,𝑖)
𝑖
 
Linear in logistic approximation: 
r = 𝑟0 + 𝑘𝑙𝑛 (
𝑒
𝑒0
) + ∑ 𝑘𝑖ln (
𝑐𝑖
𝑐0,𝑖
)
𝑖
 
Mass action in S-systems: 
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S-systems are nonlinear approximation models using power-law formalism [66].  
r = 𝑟0𝑘
𝑒
𝑒0
∏(
𝑐𝑖
𝑐0,𝑖
)𝑘𝑖
𝑖
 
Thermokinetic, linear-logistic models: 
r =
𝑒
𝑒0
(𝑘 + ∑ 𝑘𝑖ln (
𝑐𝑖
𝑐0,𝑖
））
𝑖
 
Michaelis-Menton models:  
r = e(∏
𝑐𝑖
𝑘𝑖 + 𝑐𝑖
− 𝐾 ∏
𝑐𝑗
𝑘𝑗 + 𝑐𝑗
)
𝑗𝑖
 
As a result, the reaction rate formula can be summarized as: 
𝑟𝑗 = 𝑟𝑗
𝑚𝑎𝑥(𝑒𝑗)𝑓𝑗(𝑐𝑗, 𝑝𝑗) 
r : reaction rate, e : enzyme, ci, cj :concentration of metabolite, i, j, K: 
𝑘−1
𝑘
, k, ki : 
kinetic parameters, r0, e0, c0: initial value. 
Based on all these discussed above, we can derive the differential equations.  
 
Figure 18. Simplified diagram pathway 
Differential equations are as below [67]. 
 
𝑑𝐸
𝑑𝑡
= 𝑘1[𝑂] − 𝑘1−[𝐸] + 𝑘2[𝐷] − 𝑘2−[𝐸] − 𝑘𝑐𝑎𝑡1[𝑂𝑀] − 𝑘𝑐𝑎𝑡2[𝐷𝑀] 
 
𝑑𝑂
𝑑𝑡
= −𝑘1[𝑂] + 𝑘1−[𝑂] − 𝑘𝑐𝑎𝑡1[𝑂𝑀] 
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𝑑𝐷
𝑑𝑡
= −𝑘2[𝐷] + 𝑘2−[𝐷] − 𝑘𝑐𝑎𝑡2[𝐷𝑀] 
 
𝑑𝑂𝑀
𝑑𝑡
= 𝑘𝑐𝑎𝑡1[𝑂𝑀] 
𝑑𝐷𝑀
𝑑𝑡
= 𝑘𝑐𝑎𝑡2[𝐷𝑀] 
 
When combined with competitive inhibition rate equation: 
 
v =
𝑉𝑚𝑎𝑥×𝑆
𝐾𝑚 (1 +
𝐼
𝐾𝑖
) + S
 
 
v =
𝑑𝑂𝑀
𝑑𝑡
= 𝑘𝑐𝑎𝑡2[𝐷𝑀] =
𝑉𝑚𝑎𝑥×𝑂
𝑘1−
𝑘1
(1 +
𝐷
𝑘2−
𝑘2
) + O
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3.0 RESULTS 
3.1 STATISTICAL ANALYSIS 
I got the data from an online database, Pharmapendium 
(https://www.pharmapendium.com/#/home). This database is comprised of seven data 
types. They are pharmacokinetic data, metabolizing enzyme & transporter data, drug 
safety data, FAERS (FDA Adverse Event Reporting System) data, chemistry data, 
efficacy data and activity data. I used the FAERS data of oxycodone hydrochloride to 
investigate the significance of oxycodone safety and co-administration problem. I 
mainly utilize the columns which are primary suspect drugs, other administered drugs 
and outcomes. The interface of the oxycodone hydrochloride FAERS dataset is shown 
in Figure 19. 
 
 
 
 
Figure 19. Interface of Pharmapendium database 
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This dataset includes 40996 records in FDA adverse effects reporting system for 
oxycodone. Among these patients, 20012 have other drugs co-administered which 
means about half of the patients use other medications together with oxycodone 
hydrochloride. 13425 patients ended up dead. More than half of the dead patients 
(7530) have concurrent drug use history. According to the drug list of 
benzodiazepines family, we define the search condition as ‘Diazepam or Oxazepam or 
Alprazolam or Chlordiazepoxide or Clorazepate or Estazolam or Flurazepam or 
Temazepam or Triazolam. As a result, 4926 patients have used benzodiazepines with 
oxycodone hydrochloride. Among them, 2668 people died which means the death rate 
is 54.2%, higher than the overall statistical death rate, 32.7%. As to the 
benzodiazepines involved in death-outcome patients, 43.6% are diazepam. In addition, 
we calculate the odds ratio (OR) of benzodiazepines as: 
OR =
𝑎𝑑
𝑏𝑐
=
2668×25313
2258×10757
= 2.78 
a, b, c, d is defined as: [68] 
a= Number of exposed cases 
b= Number of exposed non-cases 
c= Number of unexposed cases 
d=Number of unexposed non-cases 
Here, for our OR value, the exposure status refers to benzodiazepines involved while 
the outcome status means death. 
In summary, about half of the Oxycodone hydrochloride users have other drugs 
administered which aggravates the fatal consequences compared with oxycodone 
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single use. The statistical result also fits the fact that the use of opioids with 
benzodiazepines is very common.  
 
Table 1 Statistical results of Pharmapendium FAERS data 
 
 
 
 
3.2 SINGLE OXYCODONE ADMINISTRATION 
To lay the foundation of DDI, we perform the single drug simulation to quantify the 
parameters and validate the model. 
3.2.1 Single dose simulation 
By searching the literature online, we will be able to determine the parameter range 
and validate the model. Currently, we choose the one-compartment model to perform 
Total number of data: 40996 
Number of patients who have other drugs administered: 20012 (48.8%) 
Number of patients whose outcome contains Death: 13425 (Overall Death Rate: 32.7%) 
Number of dead patients who have other drugs administered: 7530 (56.1% of dead patients) 
Number of patients who have benzodiazepines administered: 4926 (24.6% of other drugs) 
Number of dead patients who have benzodiazepines administered: 2668 (benzodiazepines 
death rate: 54.2%) 
Number of patients who have diazepam administered: 2148 (43.6% of benzodiazepines 
involved)  
Number of died patients who have diazepam administered: 1164 (diazepam death rate: 
54.19%) 
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the simulation.  
 
 
 
Figure 20. Diagram of one-compartment model on Simbiology 
As shown, we create a one-compartment model with bolus dosing and linear 
clearance elimination. According to a literature [69], Ka value is set between 0.13 to 
0.18 hour-1. Ke can be derived from half-life (𝑡1/2). For the first-order elimination, 
𝐾𝑒 =
0.693
𝑡1/2
 [70]. The Oxycodone half-life is about 3 to 5 hours. The Ke should be 
estimated in the range of 0.1386 to 0.231 hour-1. 
We extract the experiment data from the report of the pharmaceutical company, 
Blenheim Pharmacal, Inc. They tested the concentration-time profile under different 
dose of Oxycodone. By administering 10, 20, 40, 80, 160 mg single dose of 
Oxycodone, they attained the concentration versus time plot.  
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(a)                                          (b) 
 
 
 
 
 
               (c)                                    (d) 
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(e) 
Figure 21. Time course of Oxycodone fitting plot under different doses (a) 10mg dose  (b) 20 mg 
dose  (c) 40 mg dose  (d) 80 mg dose  (e) 160 mg dose  
In comparison to the experimental data, the simulation results can fit well. We can 
ensure the parameters as: 
Table 2. 𝐾𝑎, 𝐾𝑒 parameter values 
 
 
The table shows these values fall in the estimated range. This proves the feasibility to 
use the one-compartment model as the preliminary tool for our PK study 
 
3.2.2 Multi-dose simulation 
In real-life medication, the drug is supposed to be given in specific dose several times 
a day to maintain the drug concentration at a steady level. The concentration solution 
for multi oral dose should be: [69] 
(𝐶𝑃)𝑡(𝑠𝑖𝑛𝑔𝑙𝑒) =
𝑓𝐷
𝑉
𝐾𝑎
𝐾𝑎 − 𝐾𝑒
[exp(−𝐾𝑒𝑡) − exp(−𝐾𝑎𝑡)] 
 
(𝐶𝑝)𝑡(𝑚𝑢𝑙𝑡𝑖𝑝𝑙𝑒) = (𝐶𝑝)𝑡1 + (𝐶𝑝)𝑡2 + ⋯ ⋯ (𝐶𝑝)𝑡𝑛+1 
37 
 
 
A paper described the Oxycodone dosing problem and provided information about 
multi-dose Oxycodone concentration-time profile [71]. Single dose administration can 
reach a relatively high concentration but will be eliminated soon and lose the 
pharmacological efficacy. The multi-dose simulation of Oxycodone is as below. 
 
 
 
 
 
 
 
 
 
Figure 22. Time course of multi-dose Oxycodone 5 mg / 6 h, 24 h fitting plot 
 
 
During the 24 h time range, patients were given Oxycodone in 5 mg dose for 4 times 
(every six hours). We can see that after the first-time administration, the Cmax was up 
to 6 ng/ml as single dose. Until the third administration, the drug level keeps in a 
narrow range, between 14 ng/ml and 20 ng/ml. In the simulation, we still chose the 
parameters from that value range in Table 2. The simulation result corresponds with 
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experimental data. 
 
 
3.3 DDI SIMULATION 
To simulate the DDI between Oxycodone and Diazepam, we introduce a PK/PD 
model. There are two one-compartment models in the diagram. One represents 
Oxycodone as well as the other indicates Diazepam. In order to integrate these two 
drugs, we brought in a PD model.  
3.3.1 The rough prediction of the DDI effects 
Our proposed mechanism is the Diazepam’s inhibition to Oxycodone metabolism as, 
they bind to CYP3A4 competitively. Michaelis-Menten kinetics is used to 
mechanistically characterize their metabolism. The formation of N, O-demethylation 
metabolic products, Noroxycodone and Oxymorphine occurs in liver microsomes [72]. 
When it comes to Oxycodone metabolism, we try to simulate the profiles of the main 
metabolites, Noroxycodone and Oxymorphone. 
 
 
 
 
Oxycodone 
CYP 3A4 CYP2D6 
kcat1                   kcat2 
 
 
 
 Noroxycodone           Oxymorphone 
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                   CYP2D6                   CYP3A4 
                    kcat3                       kcat4 
 
Noroxymorphone     
    
Figure 23. Simplified Oxycodone metabolic pathway 
The reaction rates and parameter values are: 
k_bind1= [kf1, kr1] 
kcat1 =[ kf1, kr1, kc1] 
k_bind2= [kf2, kr2] 
kcat2= [kf2, kr2, kc2] 
k_bind3= [kf3, kr3] 
kcat3= [kf2, kr3, kc3] 
k_bind4= [kf4, kr4] 
kcat4= [kf4, kr4, kc4] 
kf1=1e-5, kr1= 0.05, kc=1e-1 
kf2=1e-5, kr2=1e-1, kc=1e-1 
kcat2= kcat3= kcat4 
 
Each catalytic reaction is defined as the combination of reverse binding rate and 
catalytic rate. The result is calculated by ODEs.  
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Figure 24. Time course of metabolites of Oxycodone 
 
The ratio of the two metabolites, Noroxycodone and Oxymorphone, is 4:1 which is in 
consistent with Figure 22. As is well known, the existence of Diazepam will 
undoubtedly alter the Oxycodone metabolism. Thus, in the next step, we will first 
keep the rate value the same as the single Oxycodone simulation and see the change 
on the major metabolite, Noroxycodone. 
We simplify the process as: 
 
                                            
Figure 25. Simplified DDI involved metabolic pathway 
We define the reaction rate as:  
41 
 
k_bind1= [kf1, kr1] 
k_bind2= [kf2, kr2] 
k_bin3= [kf3, kr3] 
k_bind4= [kf4, kr4] 
kcat1= [kf3, kr3, kc1] 
kcat2= [kf4, kr4, kc2] 
 
 
(a)                                  (b) 
 
 
 
(c) 
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Figure 26. Time Course of major metabolite noroxycodone under co-administration (a) kf1=1e-5  (b) 
kf1=1e-6  (c) kf1=1e-7 
By comparing Figure 22 and Figure 23. (a), we can see although each parameter 
remains unchanged, the amount of metabolite is significantly reduced in 
co-administration. On account of the competitive inhibition between Oxycodone and 
Diazepam binding with CYP3A4, the binding rate will definitely vary. As is shown in 
Figure 23. (b) and (c), if the oxycodone binding rates are decreased to 1e-6 and 1e-7, 
the amounts of Oxycodone metabolites are decreased as well. Furthermore, the 
retention time of Noroxycodone is prolonged which proves that diazepam causes the 
delay of oxycodone metabolism. Such results roughly verify our conjectures. 
 
3.3.2 PK/PD modeling for DDI simulation 
To simulate this concomitant use of Oxycodone and Diazepam, we use a PD model to 
integrate the interaction between these two drugs. 
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Figure 27. Diagram of DDI 
 
Drug A represents Oxycodone, Drug B is Diazepam. On the basis of drug labeling for 
normal patients (e.g. not for patients with withdrawal syndromes), the Oxycodone 
dose often ranges from 10 to 40 mg while the dose of Diazepam is 2, 5 or 10 mg. The 
interaction term characterizes Diazepam’s influence on Oxycodone clearance. In the 
reaction terms ‘Drug A in’ and Drug B in’, we introduce the Drug A and Drug B as 
one of the species. We presume the drug goes through the metabolism and then 
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produce pharmacological effect. We define the expression at the form of 
Michaelis-Menten kinetic equations and use a parameter fu to denote the competitive 
inhibition. The Km, Vmax values can be gained from the literature [73]. 
We select the combination of 40 mg Oxycodone + 5 mg Diazepam to perform the 
simulation. The concentration-time profile is shown as below. 
 
Figure 28. Simulated concentration-time profile of 40 mg single dose Oxycodone & 40 mg Oxycodone 
+ 5 mg Diazepam 
 
Figure 28. illustrates under the same time range 12 h, the Oxycodone concentration in 
co-administration is higher than that of single use. Using the inhibition degree R to 
characterize this co-administration, 
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This result is consistent with the prediction of major metabolite, Noroxycodone in 
section 3.3.1. As the concurrent use of Diazepam, the primary compound Oxycodone 
exists in the plasma at a higher level and longer time while the metabolite amount is 
comparatively low, shown in Figure 28. This study explains why the 
co-administration of Oxycodone and Diazepam, in other words, prescription opioids 
and benzodiazepines renders more threatening overdose morbidity and mortality. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R =
𝐴𝑈𝐶𝑝𝑜(+𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟)
𝐴𝑈𝐶𝑝𝑜(−𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟)
=
388.1532
295.0164
= 1.3157 
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4.0 CONCLUSION & FUTURE PERSPECTIVE 
4.1 CONCLUSION 
Our statistical result indicated the significance of this co-administration problem 
which exacerbates the adverse effects and increases the mortality. We have built a 
one-compartment model to simulate the Oxycodone concentration-time profile and 
validate parameter values. By constructing the co-administration model, we could 
obtain the Oxycodone concentration-time profile under concurrent use and verify our 
conjecture about the elevated AUC value. Such results allow us to draw the 
conclusion as while co-administered with Diazepam, the metabolism of Oxycodone is 
delayed which maintains the drug concentration at a relatively high level and renders 
more threatening overdose symptoms. 
Our research provides an option to quantitatively describe the drug concomitant use. 
We propose to apply the results for further investigation and real-life drug use 
guidance.  
4.2 FUTURE PERSPECTIVE 
Currently, we have only adopted a one-compartment model to conduct the simulation, 
focusing on the plasma concentration. In future studies, we will build 
multi-compartment models to characterize more detailed drug-drug interactions or 
any other type of co-administrations. 
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Neural problems are very complex and hard to fully investigate. There may be other 
causes leading to this aggravated overdose liability. In this study, we got the evidence 
from FDA drug labeling and other related literature. Reported overdose symptoms and 
side effects provide us the rationale for speculation. In this Oxycodone case, although 
the major mechanism of action indicates no overlapped pathways or targets, we 
cannot rule out the possibilities. We will further explore potential mechanisms of 
drug-drug interactions with our established computational chemogenomics 
technologies. 
So far, we have obtained all sorts of data from online resources such as databases, 
literature and case reports. Because Oxycodone and Diazepam are pervasively used 
drugs with a comparatively long history, we are able to attain the data. However, data 
are not available for all the potentially abused drugs and their combinations. To 
strictly validate the models and results, we still need to perform the experiments. We 
are supposed to collect the data from hospital emergency departments and incubate 
the liver microsomes to imitate the metabolic pathway to assess the 
drug-abuse-related co-administration. 
Finally, we intend to expand the scope of prediction. Our lab has constructed a 
chemogenomics database for drug abuse research. On the foundation of this specific 
DDI study, we propose to establish a platform for versatile drug abuse research based 
on the quantitative simulations. For example, users, like patients or physicians, input 
the drug names and will then receive all sorts of relevant information. Furthermore, 
this database can evolve into a DDI prediction tool. As long as the users are aware of 
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drug names, the platform can provide the safety information to guide use of each drug. 
The aim of our project is to identify the threat of drug-abuse-related co-administration, 
thus to better assess toxicity and improve decision making. 
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APPENDIX A. ABBREVIATION 
 
 
DDI            Drug-drug interaction 
PK             Pharmacokinetics 
PD             Pharmacodynamics 
CNS            Central nervous system 
CYP            Cytochrome P450 
FAERS          FDA adverse event reporting system 
ODE            Ordinary differential equation 
ADME          Administration, distribution, metabolism, elimination 
PBPK/PD        Physiologically based pharmacokinetic and pharmacodynamic 
MBDD          Model based drug development 
CL              Clearance 
AUC            Area under the curve 
OR             Odds ratio 
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APPENDIX B. CORE CODES 
 
#import data and function 
import pandas as pd 
import numpy as np 
data=pd.read_csv('C:/Users/ZHZ85/test/FAERS.csv',usecols=
[1,2,3,4,5,6,7,8]) 
#print the data 
data 
#print the name of each column 
data.columns 
 
#extract the Outcomes column 
data1=data.Outcomes 
#find the cells which contain Death. if so, print True; 
else,print False  
data2=data1.str.contains('Death',na=False) 
#count the number of True and False outcomes 
data2.value_counts() 
#extract the Other Administered Drugs column 
data3=data.iloc[:,2] 
#convert the data from series to array 
data4=np.array(data3)  
#restrict the format of blank cells and replace them by 0 
a=data3[1] 
for i in data4: 
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    if i ==a: 
        data5=data3.replace(i,0) 
data6=np.array(data5) 
#count the number of nonzero values in the array  
cnt=np.count_nonzero(data6) 
#print the number of patients who have other drugs 
administered 
Cnt 
 
data7=np.array(data2)    
# find the place of nonzero values   
indice=np.where(data6!=0) 
#set the values of corresponding place: if this place is True, 
set the value as 1; else, set the value as 0. Calculate the 
sum value of the array. 
for j in indice: 
    data8=data7[j] 
for i in data8: 
    if i=='True':  
        i=1 
    else: 
        i=0 
#print the number of died patients who have other drugs 
co-administered 
print np.sum(data8) 
 
#filter the cells that contain benzodiazepines 
data9=data3.str.contains('Diazepam|Oxazepam|Alprazolam|Ch
lordiazepoxide|Clorazepate|Estazolam|Flurazepam|Temazepam
|Triazolam') 
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#replace those cells with True, else, with False 
data9.value_counts() 
data10=np.array(data9) 
data11=data10.astype(int)  
indice2=np.where(data11==1) 
for j in indice2: 
    data12=data7[j] 
for i in data12: 
    if i=='True': 
        i=1 
    else: 
        i=0 
#print the number of dead patients who have benzodiazepines 
administered 
print np.sum(data12) 
 
#filter the cells that contain benzodiazepines 
data13=data3.str.contains('Diazepam') 
data13.value_counts() 
data14=np.array(data13) 
data15=data14.astype(int) 
indice3=np.where(data15==1) 
for j in indice3:  
    data14=data7[j] 
for i in data14: 
    if i=='True': 
        i=1 
    else: 
        i=0 
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#print the number of dead patients who have diazepam 
administered 
print np.sum(data14) 
 
# obtain the number of dead patients who do not have 
benzodiazepines 
data9.value_counts() 
indice4=np.where(data11==0) 
for i in indice4: 
    data16=data7[i] 
for i in data16: 
    if i=='True': 
        i=1 
    else: 
        i=0 
print np.sum(data16) 
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#import functions 
from pysb import * 
from pysb.macros import catalyze 
from pysb.macros import catalyze_one_step 
from pysb.macros import bind 
from pysb.integrate import odesolve 
from matplotlib import pyplot as plt 
import numpy as np 
 
# define all the below codes into a model 
Model() 
 
#set the parameter values 
kf1= 1e-5 
kr1= 0.05 
kc1 = 1e-1 
klist1 =[kf1, kr1] 
klist_cat1 = [kf1,kr1,kc1] 
kf2= 1e-5 
kr2= 1e-1 
kc2 = 1e-1 
klist2 =[kf2, kr2] 
klist_cat2 = [kf2,kr2,kc2] 
 
#set the initial values 
Parameter('CYP3A4_0',10000) 
Parameter('oxycodone_0',20000) 
Parameter('CYP2D6_0',6000) 
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# define all the mentioned substance as monomer form 
Monomer('oxycodone',['a','b']) 
Monomer('CYP3A4',['a','d']) 
Monomer('CYP2D6',['b','c']) 
Monomer('noroxycodone',['c']) 
Monomer('oxymorphone',['d']) 
Monomer('noroxymorphone',['e']) 
 
# set the primary compound as initial 
Initial(CYP3A4(a=None,d=None),CYP3A4_0) 
Initial(oxycodone(a=None,b=None),oxycodone_0) 
Initial(CYP2D6(b=None,c=None),CYP2D6_0) 
 
# define the reactions involved in oxycodone metabolic pathway 
catalyze(CYP3A4(),'a',oxycodone(),'a',noroxycodone(c=None),klist_cat1
) 
catalyze(CYP2D6(),'b',oxycodone(),'b',oxymorphone(d=None),klist_cat2) 
catalyze(CYP2D6(),'c',noroxycodone(),'c',noroxymorphone(e=None),klist
_cat2) 
catalyze(CYP3A4(),'d',oxymorphone(),'d',noroxymorphone(e=None),klist_
cat2) 
 
# set the output compound as observable 
Observable('onor',noroxycodone(c=None)) 
Observable('ooxy',oxymorphone(d=None)) 
 
# calculate the ODE 
t= np.linspace(0, 3600) 
out = odesolve(model, t) 
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# plot 
plt.plot(t,out['onor'],label='noroxycodone') 
plt.plot(t,out['ooxy'],label='oxymorphone') 
plt.xlabel("Time(s)") 
plt.ylabel("Amount") 
plt.legend(loc='best') 
plt.show() 
 
 
#import functions 
from pysb import * 
from pysb.macros import catalyze 
from pysb.macros import catalyze_one_step 
from pysb.macros import bind 
from pysb.integrate import odesolve 
from matplotlib import pyplot as plt 
import numpy as np 
# define the whole thing as a model 
Model() 
 
#set the parameter values 
kf_bind1 = 1e-7 
kr_bind1 = 0.15 
kcat = 1e-1 
kf_bind2=1e-5 
kr_bind2=1e-1 
klist_bind1=[kf_bind1, kr_bind1] 
klist_bind2=[kf_bind2, kr_bind2] 
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klist_cat1 = [kf_bind1,kr_bind1,kcat] 
klist_cat2 = [kf_bind2,kr_bind2,kcat] 
 
#set the initial values 
Parameter('CYP3A4_0',10000) 
Parameter('oxycodone_0',20000) 
Parameter('CYP2D6_0',6000) 
Parameter('diazepam_0',5000) 
Parameter('UGT_0',5000) 
Parameter('kc',1e-1) 
 
# define all the mentioned substance as monomer form 
Monomer('oxycodone',['a']) 
Monomer('diazepam',['b']) 
Monomer('CYP3A4',['a','b']) 
Monomer('noroxycodone',['c']) 
Monomer('CYP2D6',['c']) 
Monomer('noroxymorphone',['e']) 
Monomer('oxyzepam',['d']) 
Monomer('UGT',['d']) 
Monomer('ugtp',['f']) 
# set the primary compound as initial 
Initial(oxycodone(a=None),oxycodone_0) 
Initial(diazepam(b=None),diazepam_0) 
Initial(CYP3A4(a=None,b=None),CYP3A4_0) 
Initial(CYP2D6(c=None),CYP2D6_0) 
Initial(UGT(d=None),UGT_0) 
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# define the binding and catalytic reactions during Oxycodone and Diazepam 
co-administration 
bind(CYP3A4(),'a',oxycodone(),'a',klist_bind1) 
bind(CYP3A4(),'b',diazepam(),'b',klist_bind2) 
Rule('CYP3A4_catalyze',CYP3A4(a=1,b=2)%oxycodone(a=1)%diazepam(b=2)>>
CYP3A4(a=None,b=None)+oxyzepam(d=None)+noroxycodone(c=None),kc) 
catalyze(CYP2D6(),'c',noroxycodone(),'c',noroxymorphone(e=None),klist
_cat2) 
catalyze(UGT(),'d',oxyzepam(),'d',ugtp(f=None),klist_cat2) 
 
# set Noroxycodone as the output 
Observable('onor',noroxycodone(c=None)) 
 
# calculate the ODE 
t= np.linspace(0, 3600) 
out = odesolve(model, t) 
 
# plot 
plt.plot(t,out['onor'],label='noroxycodone') 
plt.xlabel("Time(s)") 
plt.ylabel("Amount") 
plt.legend(loc='best') 
plt.show() 
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